SCHEDULE 13G/A: Bank of America Discloses 2.2% Passive Stake in Caribou Biosciences

Bank of America Corporation has filed an amended Schedule 13G, disclosing a 2.2% passive beneficial ownership stake in Caribou Biosciences, Inc. as of December 31, 2024.

Summary

• Bank of America Corp /DE/ has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Caribou Biosciences, Inc.
• The filing indicates that Bank of America Corp /DE/ beneficially owns an aggregate of 1,951,065 shares of Caribou Biosciences, Inc. Common Stock.
• This ownership represents 2.2% of the class of securities.
• Bank of America Corp /DE/ holds 0 shares with sole voting power and 1,649,066 shares with shared voting power.
• The entity holds 0 shares with sole dispositive power and 1,951,065 shares with shared dispositive power.
• The filing was made under Rule 13d-1(b), indicating a passive investment purpose, not for changing or influencing control of the issuer.
• Bank of America Corporation filed on behalf of itself and its wholly-owned subsidiaries, including Bank of America N.A., BofA Securities, Inc., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc., which are classified as a bank, broker-dealers, and a non-U.S. institution.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory disclosure of beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the issuer's performance or outlook. It is neutral in tone and content.

Future Outlook

This document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Caribou Biosciences, Inc.'s future performance or outlook.

Industry Context

This Schedule 13G filing is a routine disclosure of passive institutional ownership. It does not provide insights into broader industry trends or competitive positioning for Caribou Biosciences, Inc., as its primary purpose is to report a significant, non-controlling stake by a financial institution.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, passive institutional holding by Bank of America, confirming a large financial entity's investment in Caribou Biosciences. This is generally viewed as a neutral to slightly positive signal, indicating institutional interest without implying control changes.

Key Dates

Keywords

Caribou Biosciences, Bank of America, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Institutional Ownership